[9][5][6][7][10] Lurbinectedin is indicated for the treatment of adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Active transcription is the process by which there are specific signal where information contained in the DNA sequence is transferred to an RNA molecule.

It is at these precise spots that slides down the DNA to produce RNA polymerase II that is blocked and degraded by lurbinectedin.

[7][10] Participants received lurbinectedin 3.2 mg/m2 by intravenous infusion every 21 days until disease progression or unacceptable toxicity.

[7] The trial was conducted at 26 sites in the United States, Great Britain, Belgium, France, Italy, Spain and Czech Republic.

[medical citation needed] While overall survival in this trial is not yet known, response rates at second line were Lurbinectedin is available in the U.S. under Expanded Access Program (EAP).